Sandbox/Alejandro: Difference between revisions

Jump to navigation Jump to search
Line 135: Line 135:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Liposomal Amphotericin B]] 3 mg/kg/day IV × 1-2 weeks'''''  <br> OR <br> ▸ '''''[[Amphotericin B]] deoxycholate 0.7-1 mg/kg/day IV × 1-2 weeks'''''<br> OR <br> ▸ '''''[[Amphotericin B lipid complex]] 5 mg/kg/day IV × 1-2 weeks'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[['''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Voriconazole]]''''' Caspofungin
|}
|}
|}
|}
Line 232: Line 232:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[▸ '''''[[Acyclovir]] x 7-10 days''''' <br> OR <br>▸ '''''[[Famciclovir]] x 7-10 days''''' <br> OR <br> ▸ '''''[[Valacyclovir]] x 7-10 days'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Acyclovir]] 10 mg/kg IV (infusion over 1 hour) q8h x 7-10 days''''' <br> OR <br>▸ '''''[[Famciclovir]] x 7-10 days''''' <br> OR <br> ▸ '''''[[Valacyclovir]] x 7-10 days'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
Line 246: Line 246:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Acyclovir]] x 7 days''''' <br> OR <br>▸ '''''[[Famciclovir]] x 7 days''''' <br> OR <br> ▸ '''''[[Valacyclovir]] x 7 days'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Acyclovir]] 10 mg/kg IV (infusion over 1 hour) q8h x 7-10 days'''''  
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[Famciclovir]] PO x 7 days''''' <br> OR <br> ▸ '''''[[Valacyclovir]] PO x 7 days'''''
|}
|}
|}
|}

Revision as of 16:50, 4 June 2014

Neutropenia and Cellular Immune Deficient Patients

▸ Click on the following categories to expand treatment regimens.

Neutropenia

  ▸  Gram-Negative Bacteria

  ▸  Gram-Positive Bacteria

  ▸  Fungi


Cellular Immune Deficiency

Bacteria

  ▸  Nocardia spp

  ▸  Atypical mycobacteria

Fungi

  ▸  Cryptococcus spp

  ▸  Histoplasma spp

Viruses

  ▸  Varicella-zoster virus

  ▸  Herpes simplex virus

  ▸  Cytomegalovirus


Gram-Negative Bacteria
Preferred Regimen
[[
Alternative Regimen
▸ '''''
Gram-Positive Bacteria
Preferred Regimen
Alternative Regimen
[[
[
Fungi
Preferred Regimen
Liposomal Amphotericin B 3 mg/kg/day IV × 1-2 weeks
OR
Amphotericin B deoxycholate 0.7-1 mg/kg/day IV × 1-2 weeks
OR
Amphotericin B lipid complex 5 mg/kg/day IV × 1-2 weeks
Alternative Regimen
Voriconazole Caspofungin
Nocardia spp
Preferred Regimen
TMP-SMX x 3-12 months
Alternative Regimen 1
Sulfadiazine 2-4 g PO 1 dose
FOLLOWED BY
Sulfadiazine 2-4 g/day PO q4-8h x 3-12 months
Alternative Regimen 1
Imipenem 250-500 mg IV q6-8h x 3-12 months
Atypical mycobacteria
Preferred Regimen
[[
Alternative Regimen
[[
Cryptococcus spp
Preferred Regimen
Moderate Severe to Severe Disease
Liposomal Amphotericin B 3 mg/kg/day IV × 1-2 weeks
OR
Amphotericin B deoxycholate 0.7-1 mg/kg/day IV × 1-2 weeks
OR
Amphotericin B lipid complex 5 mg/kg/day IV × 1-2 weeks
FOLLOWED BY
Itraconazole 200 mg PO q12h x ≥12 months
Mild to Moderate Disease
Itraconazole 200 mg PO q12h x ≥12 months
Adapted from Clin Infect Dis. 2007;45(7):807-25.[1]
Histoplasma spp
Preferred Regimen
Liposomal Amphotericin B 3 mg/kg/day x 1- 2 weeks
OR

Amphotericin B lipid complex 5 mg/kg/day x 1- 2 weeks

FOLLOWED BY
Itraconazole 200mg q8h x 3 days
FOLLOWED BY
Itraconazole 200mg q12h x 6-12 months
Varicella-zoster virus
Preferred Regimen
Acyclovir 10 mg/kg IV (infusion over 1 hour) q8h x 7-10 days
OR
Famciclovir x 7-10 days
OR
Valacyclovir x 7-10 days
Alternative Regimen
[[
Herpes simplex virus
Preferred Regimen
Acyclovir 10 mg/kg IV (infusion over 1 hour) q8h x 7-10 days
Alternative Regimen
Famciclovir PO x 7 days
OR
Valacyclovir PO x 7 days
Cytomegalovirus
Preferred Regimen
Ganciclovir x 21 days
Alternative Regimen
[[
  1. Wheat, LJ.; Freifeld, AG.; Kleiman, MB.; Baddley, JW.; McKinsey, DS.; Loyd, JE.; Kauffman, CA. (2007). "Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America". Clin Infect Dis. 45 (7): 807–25. doi:10.1086/521259. PMID 17806045. Unknown parameter |month= ignored (help)